EGF Receptor pY1173 Antibody, anti-human, REAfinity™
Synonyms: EGFR, ERBB, HER1, NISBD2, PIG61, erbB-1
RECOMBINANT EXTENDED VALIDATION
Clone:
REA696 | EM-13
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
ICFC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for EGF Receptor pY1173 Antibody, anti-human, REAfinity™

Intracellular flow cytometry applications
APC
PE
Recommended dilution:
1:50
Remark:
The antibody is suited for staining of formaldehyde-fixed cells.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-110-600, 130-110-542
Description:
A431 cells, either left unstimulated (left peak) or stimulated with 200 ng/mL human EGF for 5 minutes at 37 °C, were fixed and permeabilized using the Cell Signaling Buffer Set A followed by an intracellular staining with Anti-EGF Receptor pY1173 antibodies. Cells were analyzed by flow cytometry using the MACSQuant® Analyzer. Cell debris was excluded from the analysis based on scatter signals.

Application image
Extended validation for EGF Receptor pY1173 Antibody, anti-human, REAfinity™
Specificity
Epitope competition assay

In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.

Other clones
Overlap in epitope recognition with REA696
9H2
low
EM13
high

Cells were incubated with an excess of purified unconjugated EGF Receptor pY1173 (REA696) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.

Sensitivity
Performance comparison

Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.

Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image

Flow cytometric comparison of different clones for EGF Receptor pY1173. A-431 cells were stimulates for 24 hours serum starved and either left stimulated with 200 ng/ml human EGF for 5 minutes at 37 °C. Cells were stained with a suitable counterstaining followed by a fixation and permeabilization step using Cell Signalling buffer set. Cells were then stained with EGF Receptor pY1173 antibodies and plotted against the side scatter. As a control, EGF Receptor pY1173 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris and cell doublets were excluded from the analysis based on scatter signals. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Extended-Validation detailed information image

Flow cytometric comparison of different clones for EGF Receptor pY1173 shown as histograms

Specifications for EGF Receptor pY1173 Antibody, anti-human, REAfinity™
Overview

Clone REA696 recognizes the human epidermal growth factor receptor (EGFR) antigen phosphorylated at tyrosine 1173 (pY1173). EGFR is a single-pass type I membrane protein which is also known as receptor tyrosine-protein kinase ErbB-1 or HER1. It is a critical regulator of many normal cellular processes, including cell growth, differentiation, survival, and migration. The EGFR is also implicated in pathological processes of cellular transformation and oncogenesis due to its overexpression in many types of cancers and its ability to induce morphological transformation of cultured cells and tumor formation in nude mice. Many different signaling pathways have been discovered to mediate the effects of EGF, the most notable being Ras-mitogen-activated protein kinase (MAPK) and the phosphatidylinositol 3-kinase pathways. In these pathways EGF binds to the EGFR to induce dimerization, catalytic activation, and autophosphorylation of tyrosines in the C-terminal tail of the EGFR. These phosphorylated tyrosines provide docking sites for adapter proteins such as Grb2, Shc, and Gab2 to link the receptor to the Ras-MAPK, as well as phosphatidylinositol 3-kinase pathways.

Additional information: Clone REA696 displays negligible binding to Fc receptors.

Alternative names

EGFR, ERBB, HER1, NISBD2, PIG61, erbB-1

Detailed product information

Technical specifications

Clone
REA696
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (I), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
EGF Receptor pY1173
Molecular mass of antigen [kDa]
132
Distribution of antigen
ubiquitous
Entrez Gene ID
RRID
AB_2651613, AB_2651611, AB_2651612, AB_2651610

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for EGF Receptor pY1173 Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

Citations for EGF Receptor pY1173 Antibody, anti-human, REAfinity™
Publications
  1. Ullrich, A. et al. (1984) Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309 (5967): 418-425
  2. Heisermann, G. J. et al. (1988) Epidermal growth factor receptor threonine and serine residues phosphorylated in vivo. J. Biol. Chem. 263 (26): 13152-13158